Adaptive Biotechnologies to report Q3 2026 earnings on November 4, with a webcast for investors.

Adaptive Biotechnologies announced it will release its third quarter 2026 financial results after market close on November 4, 2026. The company will host a webcast conference call for investors at 1:30 p.m. Pacific Time to discuss the results. Adaptive Biotechnologies focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases like cancer and autoimmune disorders. This earnings report will provide insights into the company's progress in its immune medicine platform and commercial products.

Adaptive Biotechnologies shares trade at USD 25.67 on Pluang, showing a 1.54% gain in the last day. The stock has a market cap of $4.04 billion and a 52-week range from $12.41 to $29.84. These figures are current as of Oct 15, 2026 03:11 WIB.